| Literature DB >> 29091768 |
Samantha J Hindle1, Roeben N Munji2, Elena Dolghih3, Garrett Gaskins4, Souvinh Orng1, Hiroshi Ishimoto5, Allison Soung6, Michael DeSalvo1, Toshihiro Kitamoto7, Michael J Keiser4, Matthew P Jacobson3, Richard Daneman8, Roland J Bainton9.
Abstract
Central nervous system (CNS) chemical protection depends upon discrete control of small-molecule access by the blood-brain barrier (BBB). Curiously, some drugs cause CNS side-effects despite negligible transit past the BBB. To investigate this phenomenon, we asked whether the highly BBB-enriched drug efflux transporter MDR1 has dual functions in controlling drug and endogenous molecule CNS homeostasis. If this is true, then brain-impermeable drugs could induce behavioral changes by affecting brain levels of endogenous molecules. Using computational, genetic, and pharmacologic approaches across diverse organisms, we demonstrate that BBB-localized efflux transporters are critical for regulating brain levels of endogenous steroids and steroid-regulated behaviors (sleep in Drosophila and anxiety in mice). Furthermore, we show that MDR1-interacting drugs are associated with anxiety-related behaviors in humans. We propose a general mechanism for common behavioral side effects of prescription drugs: pharmacologically challenging BBB efflux transporters disrupts brain levels of endogenous substrates and implicates the BBB in behavioral regulation.Entities:
Keywords: behavior; blood brain barrier; central nervous system; drug side effect mechanisms; drug transporters; endobiotics; steroid hormones; toxicology
Mesh:
Substances:
Year: 2017 PMID: 29091768 PMCID: PMC5774027 DOI: 10.1016/j.celrep.2017.10.026
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423